Portfolio
This post references, or is about Iterum. Find out more by clicking below
Useful Tools
Download, print or share this article
Stay Updated
Add your email below to stay updated with useful and informative content from Arix and our portfolio companies
11th April 2019
The highest risk of treatment failure is seen in patients previously infected with a resistant pathogen.
Sulopenem has in vitro activity against isolates of Neisseria gonorrhoeae non-susceptible to quinolones, azithromycin or β-lactams.
DUBLIN, Ireland and CHICAGO, April 11, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc, (Nasdaq: ITRM) a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, will present three posters at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Netherlands on April 15, 2019.
“The rapidly rising rates of antibacterial resistance in pathogens associated with uncomplicated urinary tract infections are making successful treatment more challenging for physicians while patients are experiencing more significant clinical consequences. The elderly and those with diabetes mellitus are especially at risk for treatment failure and need better diagnostic and therapeutic options for this disease. As with urinary tract infections, the prevalence of resistant gonorrhoeae infections is also on the rise. We believe sulopenem, which is being developed in oral and intravenous formulations, has considerable potential as an important new treatment option to help patients and physicians better address infections caused by resistant pathogens.”
Michael Dunne, M.D., Chief Scientific Officer of Iterum Therapeutics
Poster Presentation p1656. Session: Urinary tract infections. 12:30 - 1:30PM CET
A patient-specific clinical predictive model to anticipate the risk of treatment failure in uncomplicated urinary tract infections
The authors reviewed the records of 4,792 patients given oral antibiotics for uncomplicated urinary tract infections (uUTIs) and assessed the difference in 28-day outcomes for patients with a uUTI whose pathogens were susceptible to empiric therapy versus those who were non-susceptible to therapy, highlighting the risk factors associated with failure. They concluded:
Poster Presentation p1705. Session: Sexually transmitted infections complicated by antimicrobial resistance. 12:30 -1:30PM CET.
In vitro activity of Sulopenem against resistant Neisseria gonorrhoeae volunteers
Poster Presentation p1992. Session: Evaluation of diverse antimicrobials in vitro and experimental models. 1:30PM - 2:30PM CET.
Post-antibiotic and sub-inhibitory minimum inhibitory concentration effects of Sulopenem
The three posters will be available for review on Monday, April 15, 2019.